Jazz Pharmaceuticals Set to Unveil Broad Range of Neuroscientific Innovations at American Academy of Neurology’s Annual Gathering

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has revealed that it will present 13 abstracts from its extensive neuroscience portfolio and pipeline at the 76th Annual American Academy of Neurology Meeting (AAN), scheduled for April 13-18, 2024, in Denver.

Among these presentations, two will be oral presentations, showcasing encore datasets. One of these presentations will unveil findings from a real-world claims analysis indicating an elevated risk of comorbid conditions, such as stroke or cardiovascular disease, in individuals with idiopathic hypersomnia compared to those without the condition. Additionally, there will be a presentation on a post-hoc analysis from the Epidiolex® (cannabidiol) oral solution Expanded Access Program (EAP), exploring the long-term effectiveness of Epidiolex in reducing treatment-resistant focal-onset seizures.

Dr. Rob Iannone, Executive Vice President and Global Head of Research and Development at Jazz Pharmaceuticals, emphasized the significance of these presentations, highlighting the company’s leadership in sleep and rare epilepsies and its dedication to developing therapies for neurological disorders.

Key highlights of the presentations at the 2024 AAN Annual Meeting include:

  • An oral presentation on the Real-World Idiopathic Hypersomnia Total Health Model (RHYTHM) study, which compared comorbid conditions in individuals with idiopathic hypersomnia to those without the condition, emphasizing the importance of considering the patient’s full clinical profile in treatment evaluations.
  • Another oral presentation focusing on a post-hoc analysis examining the real-world outcomes and long-term effectiveness of Epidiolex in treating treatment-resistant focal-onset seizures.
  • Two posters evaluating the impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution on sleep inertia in individuals with idiopathic hypersomnia, along with results from a Phase 3 trial.
  • A poster presenting final results from the SEGUE study, demonstrating minimal dosing adjustments when transitioning adults with narcolepsy from Xyrem® (sodium oxybate) oral solution to Xywav.
  • A poster reviewing data from five clinical studies assessing the impact of high-sodium oxybates on sleep quality, sleep architecture, and disrupted nighttime sleep in narcolepsy patients.
  • Five posters examining real-world treatment patterns, effectiveness, and caregiver experiences with Epidiolex, including updated interim results from the BECOME tuberous sclerosis complex (TSC) caregiver survey and a post-hoc analysis demonstrating long-term effectiveness of Epidiolex across all focal seizure subtypes in patients with TSC.
  • Two posters featuring Jazz’s research on investigational suvecaltamide (JZP385) in essential tremor (ET) and Parkinson’s disease (PD) tremor, including insights from a systematic review of existing literature on ET epidemiology and treatment patterns, and an overview of an ongoing Phase 2 study evaluating suvecaltamide’s efficacy and safety on tremor functional impact in PD.

The abstracts for the 2024 AAN Annual Meeting can be accessed online at https://index.mirasmart.com/AAN2024/.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter